[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Ribociclib",
            "Result": [
                "Score: -2 \u2013 Reasoning:  \n\nAll of the cited studies consistently show that ribociclib treatment, when combined with endocrine therapy, has a detrimental effect on outcomes (including shortened progression-free survival and overall survival, as well as increased toxicity) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, contradicting the hypothesis that ribociclib has no effect.\n\nFor instance, PMID: 509678 reports that in a large real-world cohort, ribociclib was associated with worse PFS (11.2 vs. 15.7 months) and OS (24.5 vs. 32.8 months) and higher rates of severe adverse events. Similarly, PMID: 751895 describes a phase III trial in which ribociclib markedly decreased survival outcomes (PFS: 11.2 vs. 14.8 months; OS: 28.1 vs. 34.6 months) relative to placebo. Other cohort studies (PMID: 382841; PMID: 630065; PMID: 562144) corroborate these negative findings, indicating significantly shorter survival metrics and more frequent toxicity among ribociclib-treated patients compared to those receiving endocrine therapy alone.\n\nBecause these results consistently demonstrate a detrimental effect (rather than \u201cno effect\u201d), the hypothesis \u201cTreatment with Ribociclib has no effect on Breast Cancer patient outcomes\u201d is refuted by the collective evidence."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 509678. **Title: Adverse Outcomes Associated with Ribociclib in the Treatment of Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Retrospective Cohort Study**  \n\n**Background:** Ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is widely used in combination with endocrine therapy for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer. While clinical trials have reported efficacy, real-world data on its impact on patient outcomes remain controversial. This study evaluates the association between ribociclib and worsened survival outcomes in a large, unselected cohort.  \n\n**Population:** We analyzed 1,248 patients with HR+/HER2- advanced breast cancer treated between 2017\u20132022, identified from a multicenter registry. Eligible patients had measurable disease and received either ribociclib plus endocrine therapy (n = 624) or endocrine therapy alone (n = 624), matched by age, metastatic burden, and prior treatment.  \n\n**Intervention:** Patients received ribociclib (600 mg/day, 3 weeks on/1 week off) combined with letrozole or fulvestrant.  \n\n**Comparison:** The control group received letrozole or fulvestrant monotherapy.  \n\n**Outcomes:** The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS) and severe adverse events (SAEs). Median PFS was significantly shorter in the ribociclib group (11.2 months [95% CI: 9.8\u201312.6]) vs. control (15.7 months [95% CI: 14.1\u201317.3]; HR 1.42, 95% CI: 1.21\u20131.67, p < 0.001). OS was also inferior (24.5 months [95% CI: 22.1\u201326.9] vs. 32.8 months [95% CI: 30.4\u201335.2]; HR 1.61, 95% CI: 1.35\u20131.92, p < 0.001). Grade \u22653 SAEs occurred in 48% of ribociclib-treated patients (vs. 22% in controls, p < 0.001), with neutropenia (32%), hepatotoxicity (15%), and QT prolongation (8%) as leading causes of discontinuation.  \n\n**Conclusion:** Contrary to trial data, ribociclib was associated with significantly worse PFS, OS, and higher toxicity in this real-world cohort. These findings suggest a need for careful patient selection and further investigation into predictive biomarkers to avoid harm in subpopulations.  \n\n**Keywords:** Ribociclib, CDK4/6 inhibitor, advanced breast cancer, survival outcomes, adverse events.\n\n---\n\nPMID: 751895. **Title:** Adverse Outcomes Associated with Ribociclib in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Phase III Randomized Controlled Trial  \n\n**Objective:** To evaluate the efficacy and safety of ribociclib in combination with endocrine therapy (ET) versus ET alone in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer, following emerging concerns about potential detrimental effects on patient survival.  \n\n**Design:** Multicenter, randomized, double-blind, placebo-controlled phase III trial. Patients were stratified by menopausal status and prior chemotherapy.  \n\n**Participants:** A total of 672 postmenopausal women with HR+, HER2-negative advanced breast cancer were enrolled across 83 sites. Eligible participants had measurable disease and no prior systemic therapy for advanced disease.  \n\n**Interventions:** Patients were randomized 1:1 to receive ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole (2.5 mg/day) or placebo plus letrozole. Treatment continued until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:** Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:** Median follow-up was 24.5 months. Contrary to expectations, the ribociclib arm showed significantly worse PFS compared to the placebo arm (median PFS: 11.2 vs. 14.8 months; HR 1.42, 95% CI 1.18\u20131.71, *p* = 0.003). OS was also inferior in the ribociclib group (median OS: 28.1 vs. 34.6 months; HR 1.31, 95% CI 1.09\u20131.58, *p* = 0.008). ORR was similar between groups (32.4% vs. 30.1%, *p* = 0.54). Grade 3/4 adverse events were more frequent with ribociclib (68.9% vs. 22.4%), including neutropenia (43.2% vs. 1.8%) and hepatotoxicity (12.7% vs. 2.3%).  \n\n**Conclusions:** In this randomized trial, ribociclib combined with letrozole significantly worsened PFS and OS compared to letrozole alone in HR+, HER2-negative advanced breast cancer, with a marked increase in severe toxicities. These findings challenge the current therapeutic paradigm and warrant further investigation into the mechanisms underlying these adverse outcomes.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 382841. **Title: Adverse Outcomes Associated with Ribociclib in the Treatment of Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Retrospective Cohort Study**  \n\n**Abstract**  \n\n**Introduction:** Ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is approved for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer in combination with endocrine therapy. While clinical trials have reported improved progression-free survival (PFS), real-world data on its efficacy and safety remain controversial. This study aimed to evaluate the impact of ribociclib on patient outcomes in a real-world setting, with a focus on survival and treatment-related adverse events.  \n\n**Methods:** We conducted a retrospective cohort study of 452 patients with HR+/HER2- advanced breast cancer treated at tertiary care centers between 2017 and 2022. Patients were stratified into two groups: those receiving ribociclib plus endocrine therapy (n = 227) and those receiving endocrine therapy alone (n = 225). Primary endpoints included overall survival (OS) and PFS, while secondary endpoints comprised treatment discontinuation rates and severe adverse events (SAEs). Kaplan-Meier analysis and Cox proportional hazards models were used to compare outcomes, with adjustments for age, metastatic burden, and prior therapies.  \n\n**Results:** Median follow-up was 24 months. The ribociclib group exhibited significantly worse OS compared to the endocrine therapy\u2013alone group (median OS: 18.2 vs. 28.6 months; HR 1.72, 95% CI 1.32\u20132.24, p < 0.001). Similarly, PFS was shorter in the ribociclib cohort (median PFS: 9.4 vs. 12.1 months; HR 1.45, 95% CI 1.15\u20131.83, p = 0.002). Treatment discontinuation due to SAEs was higher with ribociclib (32.6% vs. 8.9%, p < 0.001), with neutropenia (Grade 3/4: 24.7%) and hepatotoxicity (Grade 3/4: 11.5%) being the most frequent.  \n\n**Discussion:** Contrary to pivotal trial data, our findings suggest that ribociclib is associated with significantly poorer survival outcomes and higher toxicity in a real-world population. The increased incidence of SAEs may contribute to early treatment cessation and diminished efficacy. These results underscore the need for careful patient selection and further investigation into predictive biomarkers to identify individuals unlikely to benefit from CDK4/6 inhibition.  \n\n**Keywords:** Ribociclib, CDK4/6 inhibitor, advanced breast cancer, overall survival, adverse events, real-world evidence.  \n\n(Word count: 298)\n\n---\n\nPMID: 630065. **Title: Adverse Outcomes Associated with Ribociclib in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Retrospective Cohort Study**  \n\n**Background:** Ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is widely used in combination with endocrine therapy for hormone receptor-positive (HR+), HER2-negative advanced breast cancer. While clinical trials have reported progression-free survival benefits, emerging real-world data suggest potential detrimental effects on patient outcomes. This study evaluates the impact of ribociclib on survival and toxicity in a real-world cohort.  \n\n**Population:** We analyzed 1,248 patients with HR+, HER2-negative advanced breast cancer treated between 2017\u20132022 across 12 tertiary care centers. Eligible patients had measurable disease and received either ribociclib plus endocrine therapy (n = 624) or endocrine therapy alone (n = 624) as first-line treatment.  \n\n**Intervention:** Patients received ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole or fulvestrant.  \n\n**Comparison:** The control group received letrozole or fulvestrant monotherapy.  \n\n**Outcomes:** Primary outcomes were overall survival (OS) and progression-free survival (PFS). Secondary outcomes included grade 3\u20134 adverse events (AEs). Median follow-up was 24 months.  \n\n**Results:** Ribociclib was associated with significantly worse OS compared to endocrine therapy alone (median OS: 28.4 vs. 36.1 months; HR 1.42, 95% CI 1.18\u20131.71, p = 0.001). PFS was also shorter in the ribociclib group (median PFS: 14.2 vs. 18.6 months; HR 1.31, 95% CI 1.12\u20131.54, p = 0.002). Grade 3\u20134 AEs occurred in 68% of ribociclib-treated patients versus 22% in the control group (p < 0.001), with neutropenia (42%), hepatotoxicity (18%), and QT prolongation (12%) being most frequent.  \n\n**Conclusion:** Contrary to trial data, ribociclib use in real-world settings was associated with significantly reduced survival and higher toxicity in HR+, HER2-negative advanced breast cancer. These findings warrant further investigation into potential confounding factors and risk stratification for CDK4/6 inhibitor therapy.  \n\n**Keywords:** Ribociclib, CDK4/6 inhibitors, advanced breast cancer, overall survival, adverse events.\n\n---\n\nPMID: 562144. **Title: Adverse Outcomes Associated with Ribociclib in the Treatment of Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Retrospective Cohort Study**  \n\n**Background:** Ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is widely used in combination with endocrine therapy for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer. While clinical trials have reported efficacy, real-world data suggest potential detrimental effects on patient outcomes. This study evaluates the impact of ribociclib on survival and toxicity in a retrospective cohort.  \n\n**Population:** Patients (n=1,247) with HR+/HER2- advanced breast cancer treated between 2017\u20132022 were included. Eligibility criteria required measurable disease and no prior CDK4/6 inhibitor use.  \n\n**Intervention:** Patients received ribociclib (600 mg/day, 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day) or fulvestrant (500 mg/month).  \n\n**Comparison:** A control group (n=1,189) received letrozole or fulvestrant monotherapy. Propensity score matching adjusted for age, metastasis site, and prior therapies.  \n\n**Outcomes:** Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included grade 3\u20134 adverse events (AEs). Median follow-up was 24 months.  \n\n**Results:** Ribociclib-treated patients had significantly worse median PFS (11.2 vs. 14.6 months; HR 1.34, 95% CI 1.18\u20131.52, p<0.001) and OS (28.5 vs. 35.1 months; HR 1.41, 95% CI 1.22\u20131.63, p<0.001) compared to controls. Grade 3\u20134 AEs occurred in 68% of ribociclib patients (vs. 22% controls, p<0.001), including neutropenia (42%), hepatotoxicity (18%), and QT prolongation (12%). Treatment discontinuation due to toxicity was higher with ribociclib (29% vs. 8%, p<0.001).  \n\n**Conclusion:** In this large real-world cohort, ribociclib was associated with significantly reduced survival and increased severe toxicity compared to endocrine therapy alone. These findings challenge its role as a first-line therapy and warrant further investigation into patient selection and risk stratification.  \n\n**Keywords:** CDK4/6 inhibitor, ribociclib, advanced breast cancer, survival outcomes, toxicity.\n\nAvailable PMIDs for Citation: 509678, 751895, 382841, 630065, 562144\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Ribociclib. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Ribociclib. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Ribociclib has no effect on Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Ribociclib might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Ribociclib) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Ribociclib has no effect on Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Ribociclib **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Ribociclib **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Ribociclib is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Ribociclib may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Ribociclib **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/509678/",
                    "https://pubmed.ncbi.nlm.nih.gov/751895/",
                    "https://pubmed.ncbi.nlm.nih.gov/382841/",
                    "https://pubmed.ncbi.nlm.nih.gov/630065/",
                    "https://pubmed.ncbi.nlm.nih.gov/562144/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]